Independent Financial Group LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,105 shares of the company’s stock, valued at approximately $445,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Quotient Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after purchasing an additional 177 shares in the last quarter. Certuity LLC boosted its holdings in shares of Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after buying an additional 177 shares in the last quarter. Oakworth Capital Inc. boosted its holdings in shares of Novo Nordisk A/S by 41.6% in the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after buying an additional 182 shares in the last quarter. True North Advisors LLC grew its position in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the last quarter. Finally, Asio Capital LLC raised its stake in Novo Nordisk A/S by 3.9% during the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after acquiring an additional 200 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S Price Performance
Shares of NYSE:NVO opened at $48.18 on Friday. The business’s 50 day simple moving average is $46.28 and its 200-day simple moving average is $45.72. The firm has a market capitalization of $215.12 billion, a price-to-earnings ratio of 11.31, a price-to-earnings-growth ratio of 4.39 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on NVO shares. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $65.56.
View Our Latest Stock Report on NVO
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
